X

Trial Profile

A pivotal phase III trial of ADVM 022 in wet age-related macular degeneration (AMD)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 19 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixoberogene soroparvovec (Primary) ; Aflibercept
Indications Wet age-related macular degeneration
Focus Registrational; Therapeutic Use
Sponsors Adverum Biotechnologies

Most Recent Events

17 Jul 2024 According to an Adverum Biotechnologies media release, pivotal trial design update anticipated in 4Q 2024.
08 Feb 2024 According to an Adverum Biotechnologies media release, initiation of Phase 3 trial expected first half of 2025 (H1 25).
01 Mar 2021 According to an Adverum Biotechnologies media release, the company will host a conference call on 1st March 2021 on the ADVM-022 pivotal program for the treatment of wet AMD.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com